Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes

References

• Federation ID. IDF diabetes atlas – 7th edition. 2016 [cited 2016 Mar 27]. Available from: http://www.diabetesatlas.org/resources/2015-atlas.html.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Sanofi. Efficacy and safety of insulin glargine/lixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patients. 2014. [cited 2016 Mar 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01476475.
   Google Scholar
• Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104–2114.
   PubMed Web of Science ®Google Scholar
• Heise T, Hovelmann U, Nosek L, et al. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine. Endocr Abstr. 2012;28:188.
   Google Scholar
• Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33(7):515–521.
   PubMed Web of Science ®Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859–864.
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Flint A, Olsen AK, et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2015.
   PubMed Web of Science ®Google Scholar
• Compendium EM. Xultophy 100 units/ml insulin degludec + 3.6 mg/mL liraglutide solution for injection in a pre-filled pen. 2016 [cited 2016 Apr 27]. Available from: https://www.medicines.org.uk/emc/medicine/29493.
   Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–893.
   PubMed Web of Science ®Google Scholar
• Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–2933.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898–907.
   PubMed Web of Science ®Google Scholar
• Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Bode B, Ingwersen SH, et al. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015;55(12):1369–1377.
   PubMed Web of Science ®Google Scholar
• Buse JBG, Gough SCL, Robard HW, et al., editors. Postprandial glycaemic control following a fixed-ratio combination of insulin degludec and liraglutide compared to each component individually in patients with type 2 diabetes. EASD; 2013; Barcelona (Spain). Barcelona: EASD; 2013.
   Google Scholar
• Holst JJ, Buse JB, Rodbard HW, et al. IDegLira improves both fasting and postprandial glucose control as demonstrated using continuous glucose monitoring and a standardized meal test. J Diabetes Sci Technol. 2016;10(2):389–397.
   Google Scholar
• Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;17(10):965–973.
   PubMed Web of Science ®Google Scholar
• Robard HWB, Bode BW, Harris S, et al., editors. IDegLira in insulin-naive patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or combined with metformin: the dual IV study. EASD; 2015; Stockholm (Sweden). Stockholm: EASD; 2015.
   Google Scholar
• Linjawi SB, Bode BW, Chaykin J-P, et al., editors. Efficacy and safety of IDegLira (combination of insulin degludec+liraglutide), in insulin naive patients with type 2 diabetes uncontrolled on GLP-! receptor agonist (GLP-1RA) therapy. EASD; 2015; Stockholm (Sweden). Stckholm: EASD; 2015.
   Google Scholar
• Rodbard HW, Buse JB, Woo V, et al. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. Diabetes Obes Metab. 2016;18(1):40–48.
   PubMed Web of Science ®Google Scholar
• Aroda VJ, Jaeckel E, Jarlov H, et al., editors. Similar incidence of gastointestinal side effects between IDegLira and non-glucagon-like peptide-1 receptor agonist comparators. EASD Meeting; 2015; Stockholm (Sweden). Stockholm: EASD; 2015.
   Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Gaspari T, Welungoda I, Widdop RE, et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diabetes Vas Dis Res. 2013;10(4):353–360.
   PubMed Web of Science ®Google Scholar
• Balestrieri ML, Rizzo MR, Barbieri M, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2015;64(4):1395–1406.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Mamdani M, Vilsbøll T, et al. IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy. Diabetes Ther. 2015;6(4):573–591.
   PubMed Web of Science ®Google Scholar
• Ogawa S, Nako K, Okamura M, et al. Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy. J Diabetes Investig. 2015;6(4):436–442.
   PubMed Web of Science ®Google Scholar
• Ahmann A, Rodbard HW, Rosenstock J, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2015;17(11):1056–1064.
   PubMed Web of Science ®Google Scholar
• Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Diamant M, Aroda VR, et al. Efficacy and safety of lixilan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the lixilan proof-of-concept randomized trial. Diabetes Care. 2016. PubMed ID: 27284114. [Epub ahead of print].
   Web of Science ®Google Scholar
• Handelsman YC, Dex T, Giorgino F, et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination in elderly patients with T2DM. New Orleans (LA): ADA; 2016. p. Abstract #954.
   Google Scholar
• Berria R, Guerci B, Paranjape E, et al. Improved glucose control withoutincreased hypoglycemia risk with insulinglargine/lixisenatide fixed-ratio combination (LixiLan) vs insulin glargine alone. Stockholm: EASD; 2015. p. Abstract #111.
   Google Scholar
• CDC. National diabetes statistics report 2014. 2014. [cited 2016 Mar 27]. Available from: http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html.
   Google Scholar